Skip to main content
. 2023 Oct 19;13:106. doi: 10.1186/s13613-023-01206-w

Table 1.

Characteristics of enrolled patients

All patients (n = 203) CRT (n = 50) No CRT (n = 153)
Age (years) 60 [49–70] 63 [52–73] 59 [49–70]
Sex (female) 71 (35%) 15 (30%) 56 (37%)
BMI (kg/m2) 26.1 [23.5–30.7] 25.6 [23.5–27.8] 26.1 [23.4–31.2]
SOFA score 4 [3–6] 5 [3–6] 4 [3–6]
Charlson comorbidity Index 2 [1–4] 2 [1–3] 2 [1–4]
ICU admission reason
 Medical 178 (88%) 45 (90%) 133 (87%)
  ARDS COVID 56 (28%) 19 (38%) 37 (25%)
  Septic shock 41 (20%) 9 (18%) 32 (21%)
  ARDS 17 (8%) 6 (12%) 11 (7%)
  Cardiac arrest 17 (8%) 3 (6%) 14 (9%)
  Acute liver failure 7 (4%) 2 (4%) 5 (3%)
  Othersa 40 (20%) 6 (12%) 34 (22%)
 Surgical 25 (12%) 5 (10%) 20 (13%)
  Trauma 6 (3%) 2 (4%) 4 (3%)
  Othersb 19 (9%) 3 (6%) 16 (10%)
 Laboratory data at enrollment
  Hct (%) 33 [28–38] 32 [29–38] 33 [27–38]
  Platelets (103/mm3) 202 [129–269] 199 [141–254] 207 [121–270]
  INR 1.19 [1.08–1.46] 1.2 [1.07–1.48] 1.19 [1.12–1.36]
  aPTT Ratio 0.95 [0.85–1.09] 0.95 [0.86–1.09] 0.94 [0.84–1.1]
  Fibrinogen (mg/dL) 436 [264–643] 421 [245–642] 523 [313–657]
  D-dimers (mg/dL) 3585 [1436–10476] 3585 [1357–12300] 3586 [1677–6484]
 Anticoagulation during ICU stay 185 (91%) 48 (96%) 137 (90%)
  Prophylaxis 105 (52%) 26 (52%) 79 (52%)
  Therapy 80 (39%) 22 (44%) 58 (38%)
 Antiplatelet therapy during ICU stay 43 (21%) 8 (16%) 35 (23%)
  Monotherapy 32 (16%) 7 (14%) 25 (16%)
  Double 11 (5%) 1 (2%) 10 (7%)
ECMO 21 (10%) 4 (8%) 17 (11%)
Surgical interventionc 53 (26%) 12 (24%) 41 (27%)
N. Catheters during ICU stay 2 [1, 2] 2 [1, 2] 2 [2–2]
  1 85 (42%) 9 (18%) 76 (50%)
  2 80 (39%) 29 (58%) 51 (33%)
  3 27 (13%) 9 (18%) 18 (12%)
  4 7 (3%) 2 (4%) 5 (3%)
  5 3 (2%) 0 (0%) 3 (2%)
  6 1 (1%) 1 (2%) 0 (0%)

CRT Catheter-related thrombosis, BMI, Body Mass Index, SOFA, Sequential Organ Failure Assessment; ICU, Intensive Care Unit; ARDS, Acute Respiratory Distress Syndrome; COVID, Coronavirus Disease; Hct, Hematocrit; INR, International Normalized Ratio; aPTT, activated partial thromboplastin time; ECMO, Extracorporeal Membrane Oxygenation

aIncluding asthma and chronic obstructive pulmonary disease exacerbation, cardiogenic shock, diabetic ketoacidosis, hypoglycemic coma, intoxication, heat stroke, botulinum poisoning, and status epilepticus

bIncluding lung and liver transplantation, bowel perforation and osteomyelitis

cIncluding patients admitted to ICU for surgical disease and patients who needed surgery during ICU stay for any reason